Raymond James analyst Steven Seedhouse raised the firm’s price target on Viking Therapeutics (VKTX) to $125 from $122 and keeps a Strong Buy rating on the shares. The firm notes that the two Phase 3 subQ VK2735 studies in obese and obese+T2DM patients are now expected to be initiated in the second quarter of 2025, the Phase 2 oral VK2735 Phase 2a study evaluating six dosing cohorts vs. placebo over 13 weeks is enrolling as planned with topline readout expected 2H25, and Viking added some additional details to a maintenance therapy study that will evaluate the potential for daily oral dosing and monthly subQ dosing after 4 weeks of rapid titration to high-dose subQ treatment, the analyst tells investors in a research note. These programs provide a comprehensive approach to treating a broad range of obesity patients, Raymond James says.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VKTX:
- Viking Therapeutics Reports Positive 2024 Financials and Clinical Progress
- Closing Bell Movers: Semis down sharply after results
- Viking Therapeutics reports Q4 EPS (32c), consensus (27c)
- Viking Therapeutics options imply 8.9% move in share price post-earnings
- Options Volatility and Implied Earnings Moves Today, February 05, 2025